The Middle EAST Calcimimetic Market was valued at USD 0.45 billion in 2024 and is projected to reach USD 1.20 billion by 2034, registering a CAGR of 10.0%. This growth trajectory is underpinned by a combination of increasing healthcare expenditures, rising prevalence of chronic kidney disease (CKD), and a growing awareness of the benefits of calcimimetics in managing secondary...